In a small glimmer of hope in what has been a rapidly deteriorating epidemic in the United States, the FDA yesterday voted 17-4 (with one abstention?) to approve the Pfizer/BioNTech coronavirus vaccine through an Emergency Use…
Following up on yesterday's Blog Post about the Pfizer and BioNTech announcement of a vaccine with a preliminary 90% efficacy, we now turn to the challenges of distribution. I mentioned that the vaccine, which is based…
Today Pfizer announced encouraging results of its SARS-CoV-2 vaccine co-developed with BioNTech. It demonstrates an efficacy above 90% at 7 days after the second dose is given, according to interim results from the companies' phase 3…